ESC Premium Access

Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: A 6-week randomised, multicentre, double-blind study followed by open-label phase

Congress Presentation

About the speaker

Doctor Kiran Bapatla

Novartis, Hyderabad (India)
0 follower

14 more presentations in this session

Central-acting aminopeptidase a inhibitors for new treatment of hypertension: from discovery to clinical trial.

Speaker: Doctor R. Hmazzou (Paris, FR)

Thumbnail

Thrombin generation and platelet function in patients on RAAS inhibitors

Speaker: Doctor C. Helten (Duesseldorf, DE)

Thumbnail

Factors associated with treatment and control of hypertension in a healthy elderly population free of cardiovascular disease: a cross-sectional study

Speaker: Doctor E. Chowdhury (Perth, AU)

Thumbnail

Hemodynamic management of resistant hypertension

Speaker: Doctor F. Chacon-Lozsan (Budapest, HU)

Thumbnail

Assess of angiotensin receptor blockers therapy associated to mineralocorticoid receptor antagonists or to calcium channel blockers plus hydrochlorothiazide according central haemodynamic parameters

Speaker: Doctor C. Paterno Marchioli (Castiglion Fiorentino (AR), IT)

Thumbnail

Access the full session

Poster Session 5 - Hypertension treatment: drugs and devices

Speakers: Doctor K. Bapatla, Doctor R. Hmazzou, Doctor C. Helten, Doctor E. Chowdhury, Doctor F. Chacon-Lozsan...
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations